Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198507 · ClinicalTrials.gov registry record · Phase 3
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
NCT03198507 is a Phase 3 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 455 participants.
The verdict
NCT03198507, a Phase 3 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
Study Summary
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.
Interventions
- DRUG Active Comparator
- DRUG RHB-105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2017-06-18 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03198507
The ClinicalTrials.gov registry entry for NCT03198507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active Comparator is the first listed.
NCT03198507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03198507 about?
NCT03198507 is a clinical study titled "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator". The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.
What is the current status of trial NCT03198507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2017-06-18. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT03198507?
The interventions under investigation include: Active Comparator (DRUG), RHB-105 (DRUG).
Who is sponsoring clinical trial NCT03198507?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.